Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Leo, Eugen [VerfasserIn]   i
 Scheuer, Lars [VerfasserIn]   i
 Schmidt-Wolf, Ingo G. H. [VerfasserIn]   i
 Kerowgan, Mohammed [VerfasserIn]   i
 Schmitt, Christina [VerfasserIn]   i
 Leo, Albrecht [VerfasserIn]   i
 Baumbach, Tanja [VerfasserIn]   i
 Krämer, Alwin [VerfasserIn]   i
 Mey, Ulrich [VerfasserIn]   i
 Benner, Axel [VerfasserIn]   i
 Parwaresch, Reza [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
Titel:Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma
Verf.angabe:Eugen Leo, Lars Scheuer, Ingo G. H. Schmidt-Wolf, Mohammed Kerowgan, Christina Schmitt, Albrecht Leo, Tanja Baumbach, Alwin Kraemer, Ulrich Mey, Axel Benner, Reza Parwaresch, Anthony D. Ho
E-Jahr:2004
Jahr:03 September 2004
Umfang:7 S.
Fussnoten:Gesehen am 30.06.2021
Titel Quelle:Enthalten in: European journal of haematology
Ort Quelle:Oxford : Wiley-Blackwell, 1987
Jahr Quelle:2004
Band/Heft Quelle:73(2004), 4, Seite 251-257
ISSN Quelle:1600-0609
Abstract:Fludarabine in combination with cyclophosphamide is an effective treatment for newly diagnosed as well as relapsed follicular lymphoma. The anti-CD20 antibody rituximab has been employed successfully for the same indications. No such data were available on a combined use of these agents. Therefore, we conducted a phase II study to evaluate the safety and efficacy of a combination of rituximab (375 mg/m2), fludarabine (4 x 25 mg/m2) and cyclophosphamide (1 x 750 mg/m2), for the treatment of relapsed follicular lymphoma. An unexpected, severe hematologic toxicity with significant, prolonged thrombocytopenias WHO grade III/IV in 6 (35%) of 17 patients treated in total occurred, leading to early termination of the trial. Cytologic and serologic analyses point toward a direct toxic effect. Older patients (mean age 64.7 vs. 56.5 yr) were significantly (P = 0.02) more likely to suffer from this toxicity, whereas no other clinical or hematologic parameter differed statistically between the patients suffering from thrombocytopenia and those who did not. The addition of rituximab to fludarabine/cyclophosphamide employed at doses given above in relapsed follicular lymphoma may have led to this increase in thrombocytopenias. Therefore, caution should be exercised when combining these drugs for the treatment of patients with relapsed follicular lymphoma, especially when treating older patients.
DOI:doi:10.1111/j.1600-0609.2004.00293.x
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1111/j.1600-0609.2004.00293.x
 Volltext: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0609.2004.00293.x
 DOI: https://doi.org/10.1111/j.1600-0609.2004.00293.x
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adult
 Aged
 Antibodies, Monoclonal
 Antibodies, Monoclonal, Murine-Derived
 Antineoplastic Combined Chemotherapy Protocols
 Cyclophosphamide
 Female
 Humans
 Lymphoma, Follicular
 Male
 Middle Aged
 Recurrence
 Rituximab
 Vidarabine
K10plus-PPN:1761643169
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68754441   QR-Code
zum Seitenanfang